Exploiting the antitumor effect of natural killer (NK) cells has regained interest in light of data from preclinical and clinical work on the potential of alloreactive NK cells. Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) represent the two most prevalent adult hematological malignancies in the western hemisphere. To evaluate the role of NK cells in the immune surveillance and their therapeutic potential for CLL and MM, tumor cell susceptibility to NK-mediated killing was investigated. Results show relative resistance of tumor cells from CLL as well as MM (73 and 70% of the patients, respectively) to NK-mediated killing. To gain insight into molecular mechanisms of this resistance, the expression of the tolerogenic HLA-G molecule in CLL and MM and its relevance to susceptibility to NK-mediated killing were investigated. HLA-G transcript was found in tumor cells from 89% (n ¼ 19) of CLL and 100% (n ¼ 9) of MM patients examined. HLA-G1 surface expression was observed in CLL and was very low or undetectable in MM. Notably, blocking of HLA-G1 with specific antibody on CLL samples increased their susceptibility to NK-mediated killing, demonstrating that HLA-G participates in protecting CLL cells from NK-mediated killing and may thus contribute to their immune escape in vivo.
Introduction
Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), two clonal B-cell malignancies, represent the two most prevalent adult hematological malignancies in the western hemisphere. MM is characterized by the outgrowth of malignant plasma cells and their accumulation within the bone marrow, which provides the appropriate support for myeloma cell growth and survival. 1 CLL is characterized by an accumulation of clonal B cells in the bone marrow, blood and lymphoid organs. 2 Despite initial response to conventional treatments and promising results with newer agents, such as immunomodulatory drugs (Thalidomide, Revlimid), proteasome inhibitors (Velcade) and antibody-based immunotherapy, success has been hindered by the emergence of resistant clones, or no response, and MM and CLL remain incurable. 3, 4 Cellular immunotherapy exploiting the antitumor effect of immune effector cells provides an attractive treatment modality, potentially complementing these drugs, and particularly aiming at the eradication of minimal residual disease. Currently, hematopoietic stem cell transplantation, in particular allogeneic stem cell transplantation, that exploits the antitumor effect of immune effector cells can be considered the only potentially curative strategy. 5, 6 Natural killer (NK) cells are important components of this antitumor activity and NK-based immunotherapy represents a promising approach, which is particularly interesting in the setting of stem cell transplantation where tumor burden is low. Moreover, combining different therapeutic modalities that target the tumor cell through different mechanisms is expected to be more effective in eliminating tumor cells and to provide means for the development of curative strategies for CLL and MM.
Natural killer cells are important effectors of innate immunity and regulators of adaptive immunity via production of various cytokines. 7, 8 NK cells, particularly upon activation with different cytokines, are able to kill tumor cells without prior sensitization and, therefore, play an important role as a first-line defense in the control of malignancies. However, some tumors escape this immune surveillance. The occurrence of malignancies resulting via tumor escape from the immune system may be due to either a defective immune function, in particular of NK cells, or to inherent features of tumor cells causing lack of recognition by NK cells and their subsequent activation to fulfill their effector function. Thus, elucidating those aspects regulating NK interaction with tumor cells is important to understand the role of NK cells in the control of malignancies as well as their potential as a means of immunotherapy for these diseases. NK cytotoxic activity is regulated by a fine balance between signals through activating and inhibitory receptors expressed by NK cells. Inhibitory receptors regulating NK effector functions bind to MHC class I molecules or their homologs on target or opposing cells. 9, 10 According to the 'missing self' hypothesis, NK cells recognize and kill tumor cells mainly because of their lack of or altered expression of MHC-class I molecules. 11 Because of the lack of inhibitory receptors corresponding to MHC class I antigens present on target cell, NK cells from allogeneic donors are believed to be more effective in killing tumor cells. This has encouraged a body of preclinical and clinical work on the basis of using allogeneic NK cells to eliminate tumor cells and generated a renewal of interest in the development of NK-based immunotherapy for the treatment of malignancies and in particular hematological malignancies. [12] [13] [14] Most NK inhibitory receptors are clonally distributed and present on only a small proportion of circulating NK cells, however, receptors for the nonclassical HLA class I molecule, HLA-G, namely ILT2 /LIR1/CD85j 15, 16 and KIR2DL4, 17 are not clonally distributed. KIR2DL4 is expressed on all NK cells of an individual and ILT2 on a subset of NK cells varying in size among different donors. HLA-G expression by tumor cells may therefore represent a more universal mechanism of tumor escape from NK rejection.
HLA-G is distinct from the other HLA class I molecules as it exhibits limited polymorphism, restricted tissue distribution and a number of protein variants. Alternative splicing of the primary transcript can generate four membrane-bound (G1-G4) and three soluble (G5-G7) isoforms. 18 HLA-G1 may also be found as a soluble protein upon cleavage from cell surface. HLA-G is expressed physiologically on cytotrophoblasts at the fetomaternal interface, where it plays an important role in maternal tolerance of the semiallogenic fetus. 19, 20 Further, HLA-G expression has been reported in a number of malignancies 21 where it may function as a means of tumor escape from immune surveillance. [21] [22] [23] Membrane-bound and soluble HLA-G exerts immunosuppressive effects via interaction with inhibitory receptors ILT2, ILT4 and KIR2DL4, differentially expressed by NK, T cells and antigen-presenting cells. 18, 21 Alternatively, HLA-G may serve as a leader sequence allowing for the expression of HLA-E, a cell surface inhibitory protein for which most NK cells express the receptor (CD94/NKG2A/B). 24 Recently, a new pathway of immune suppression by HLA-G has been described, which is mediated by immunosuppressive T and NK cells generated by acquisition of HLA-G through a process of membrane transfer called 'trogocytosis'. 25, 26 The impact of this immune suppression can, therefore, be beneficial or detrimental depending on its scope, since by its immunoregulatory role, it may facilitate the acceptance of the fetus, allografts and tumors.
The aim of this study was to investigate the expression of HLA-G in CLL and MM and determine its relevance in tumorcell susceptibility to NK-mediated killing. Here, we report the expression of multiple HLA-G mRNA isoforms by tumor cells from CLL and MM patients, while being absent from normal counterparts. Furthermore, we found that these cells were mostly resistant to NK-mediated killing and that blocking of membrane-bound HLA-G on CLL samples increased their susceptibility to NK-mediated killing. We propose that HLA-G participates in protecting CLL cells from NK-mediated attack and contributes to their immune escape. These data justify further investigation into the role of HLA-G expression on tumor cells of B origin in the pathophysiology of the disease.
Materials and methods

Patient samples and cell lines
Peripheral blood from 19 patients with the diagnosis of CLL, bone marrow aspirates from 13 myeloma patients, peripheral blood and bone marrow aspirates from healthy volunteers as control were obtained according to institutional review board approval.
Peripheral blood and bone marrow mononuclear cells (PBMC) were isolated by density centrifugation on FicollHypaque (Pharmacia, Amersham Pharmacia, Uppsala, Sweden). B lymphocytes were then isolated by negative selection magnetic bead using a B-cell isolation kit (Miltenyi Biotech, Auburn, CA, USA), and myeloma cells by CD138 magnetic bead selection. NK cells were isolated by negative selection using an NK cell isolation kit (Miltenyi Biotech) from healthy donors' peripheral blood mononuclear cells (PBMCs) and kept briefly on low-dose IL-2. NK-sensitive erythroleukemia cell line K562, myeloma cell lines U266, RPMI 8226, IM9, the M8 melanoma cell line and its stable transfectant M8-HLA-G1 were used as target for NK-mediated cytotoxicity assay and maintained in culture in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). NK-92, a highly cytotoxic human NK cell line, with characteristics of activated NK cells 27, 28 was used as an effector cell population and maintained in X-VIVO 10 supplemented with 5% human AB serum and 100 U ml -1 interleukin-2 (Chiron, Emervyille, CA, USA). All cell lines were obtained from ATCC (Manassa, VA, USA).
Reagents, antibodies and flow cytometry B-cell isolation kit, CD138 micro beads, NK-cell isolation kit and MACS columns were obtained from Miltenyi Biotech.
The following conjugated monoclonal antibodies (mAbs) were used in this study: CD5-FITC, CD19-PE, CD20-FITC and -PE, CD45-FITC, CD56-FITC and -PE, CD16-FITC (all from BD Bioscience/BD Pharmingen, San Diego, CA, USA), CD138-PE, CD107a-FITC clone H4A3 (IgG1) from Diaclone (Besançon, France). The HLA-G-specific antibodies recognizing membranebound HLA-G1 isoform were used: clone MEM-G/9 (mouse IgG1) was obtained from Serotec (Raleigh, NC, USA), and clone 87G (IgG2a) from Exbio (Prague, Czech Republic Cr release assays as previously described. 27 Briefly, target cells were labeled with 50 mCi Na 2 51 CrO 4 (New England Nuclear, Boston, MA, USA) and resuspended at 1 Â 10 5 cells ml -1 , 100 ml of target cells were mixed in triplicate with 100 ml of effector NK cells at various effector/target (E/T) cell ratios ranging from 20:1 to 1:1. For determination of spontaneous release, target cells were incubated with medium alone and for maximum release, with lysing solution (complete medium þ 10% Triton X-100). Following incubation for 4 h, 100 ml of supernatant was transferred to Ready Cap filter scintillants (Beckman Fullerton, CA, USA) and the amount of 51 Cr released due to target cell lysis was measured using a Beckman LS6000 scintillation counter.
Calcein assay. Target cells were labeled with 12.5 mM Calcein AM (Molecular Probes, Eugene, OR, USA) 29 and washed twice with phosphate-buffered saline þ 5% FBS (PBS-FBS) and resuspended at 1.5 Â 10 5 cells ml -1 . A quantity of 100 ml of target cells was mixed in triplicate with 100 ml of effector NK cells and was added to each well at various E/T ratios ranging from 10:1 to 1:1. For spontaneous release, target cells were incubated with medium alone (PBS-FBS) and for maximum release with lysing solution (50 mM sodium tetraborate þ 0.1% Triton X-100, pH 9.0). After 3 h incubation at 37 1C, 150 ml of supernatant was removed from each well and transferred to a 96-well flat bottom microtiter plate and fluorescence measured on a Cytofluor II Fluorescence Plate Reader. The specific cytotoxicity in percent was determined as the ratio of experimental release to maximum release (both corrected for spontaneous release).
HLA-G-blocking cytotoxicity assay. For HLA-G blocking experiments, target cells were incubated with azide-free HLA-G mAb 87G at a concentration of 10 mg ml -1 for 30 min prior to coincubation with NK cells and then cytotoxicity assay (CD107 mobilization or CytoxiLux) was performed as described.
CytoxiLux PLUS assay. The CytoxiLux PLUS assay (OncoImmunin, Inc., Gaithisburg, MD, USA) is a fluorogenic cytotixicity assay measuring the activation of the caspase pathway, which results in the development of a green fluorescence due to the cleavage of a cell-permeable fluorogenic caspase substrate. 30 Briefly, target cells were fluorescently labeled (FL2 channel, red fluorescence) and then incubated with effector cells for 90 min at 37 1C in 5% CO 2 . Cells were then washed and further incubated for 30-45 min in the presence of a fluorogenic caspase substrate (FL1 channel, green fluorescence). Following incubation and washing, samples were analyzed by flow cytometry. Cleavage of the caspase substrate results in increased green fluorescence in dying cells, which will be visualized as double positive events.
CD107mobilization assay. A recently developed flow
cytometry-based CD107 mobilization assay 31, 32 was used to evaluate the effect of blocking HLA-G on CLL cells and their sensitivity to NK-mediated killing. CD107a is expressed in the membrane of cytotoxic granules of cytotoxic lymphocytes and become exposed on the cell surface upon degranulation. This is a measurement of effector activation to kill the target cells rather than the lysis of the target cells and thus provides an accurate assessment of the impact of inhibitory signals.
Effector NK-92 and target CLL cells were washed twice and suspended in complete medium (RPMI1640 supplemented with 5% human AB serum) at cell density of 1 Â 10 6 ml -1 (NK cell) and 5 Â 10 6 ml -1 (target cells). A quantity of 100 ml of each effector and target cells were mixed and coincubated for 4 h at 37 1C in 5% CO 2 . Thereafter cells were stained with anti-CD56-PE (NK marker) and anti-CD107a-FITC. Cells were then washed twice and suspended in PBS-FBS (2%), and analyzed by flow cytometry.
RT-PCR analysis
Isolated CLL and MM pellets were lysed in Trizol (Invitrogen, Carlsbad, CA, USA) at a concentration of 1 Â 10 6 cells ml . Fifteen-microliter aliquots of each reaction were resolved on 1% agarose and representative bands were excised, purified and sequenced to confirm their identities.
Results
Tumor cells from CLL and myeloma patients are resistant to NK-mediated killing
Nineteen CLL and ten myeloma patients followed at Rush University Medical Center were included in this study. The median age was 59 years (range, 38-80years) for CLL patients and 57 years (range, 44-70 years) for myeloma patients. The percentage of CLL cells in the blood at the time of the study ranged from 60 to 97% (Table 1a ). Four of the CLL patients had been treated and all others had not required treatment. The Table 1a Chronic lymphocytic leukemia (CLL) patients' characteristics Because of the lack of inhibitory receptors corresponding to MHC class I antigens present on target cells, NK cells from allogeneic donors are believed to be more effective in killing tumor cells. Moreover, NK activity is often altered in these patients. [33] [34] [35] We tested the sensitivity of patient-derived tumor cells to NK cells from unrelated healthy donors as well as NK-92, a highly cytotoxic human NK cell line with characteristics of activated NK cells 27, 28 and which represents a model system to investigate susceptibility to NK-mediated killing and mechanisms of tumor escape.
Susceptibility of CLL cells to NK-mediated killing was determined on B cells isolated from patient PBMCs, using a B-cell isolation kit, or on unselected PBMCs when the percentage of CLL cells was determined as X90% via coexpression of CD19 and CD5. Calcein assay and flow cytometry-based cytotoxicity assays were performed as described for 19 CLL patients (Figure 1 ) and even at the highest effector to target ratio of 20:1 at the best 25% of CLL cells were lysed. Only five CLL samples were relatively sensitive to killing by NK-92 cells (X15% killing at an E/T ratio of 20:1) (Figure 1a) , while all others were mostly resistant ( no killing or less than 10% killing at an E/T ratio of 20:1) (Figure 1b ). These results demonstrate CLL tumor cell resistance to NK-mediated killing.
Parallel experiments investigated the sensitivity of MM cells to NK-mediated killing. CD138 is a marker for plasma cells and the pattern of expression of CD138 and CD45 allows discrimination between normal and malignant plasma cell (myeloma cells). 36 Myeloma cells were isolated by CD138 selection of bone marrow aspirates from 10 myeloma patients and myeloma-cell susceptibility to NK-mediated killing was evaluated using both these patient-derived myeloma cells and myeloma cell lines (Figure 1 ). Myeloma cell lines were sensitive to NK-mediated killing (Figure 1c ) while patient-derived primary myeloma cells were mostly resistant in these assays demonstrated by only 15% cytotoxicity at the greatest effector/target ratio of 10:1 (Figure 1d ).
These data show general resistance of primary CLL and myeloma cells to NK-mediated killing. CLL tumor cells were resistant to NK-92-mediated killing, with cytotoxic values of 7.9% ± 1.8, 5.4% ± 1.4 and 3 ± 1 at E/T ratio of 20:1, 10:1 and 5:1, respectively (n ¼ 19), while MM cells were killed at 6.9% ± 2, 1.9% ± 2.2 and 0.5% ± 0.2 at 10:1, 5:1 and 1:1, respectively (n ¼ 10). No killing of primary bone marrow CD138 þ plasma and B cells from healthy donors was observed (data not shown).
HLA-G is expressed on CLL and myeloma cells
To gain insight into the mechanism responsible for this NK resistance, expression of HLA-G and its isoforms on CLL cells was investigated as the expression of HLA-G has been demonstrated in other malignancies to impede NK-mediated killing.
22,23 B cells isolated from PBMCs of CLL patients were analyzed by flow cytometry and RT-PCR. Surface expression of HLA-G was determined by staining with mAb MEM-G/9, which detects the full-length isoform HLA-G1. Since current commercially available antibodies allow only the detection of HLA-G1/ G5 isoforms, PCR analysis was performed in parallel to more fully characterize HLA-G expression. Representative PCR bands were purified and sequenced to confirm the HLA-G variants expressed by each sample, and the results are listed in Table 1a . Surface expression of HLA-G on CLL cells varied between 1.5 to 17% of cells (Figure 2) . With the exception of 2 (CLL1 and CLL6) of 19 CLL patients examined, HLA-G transcripts were detected in CLL samples for at least one HLA-G isoform by PCR (Table 1a ). All samples exhibiting cell surface HLA-G had concordant expression of the HLA-G1/5 transcript by molecular analysis. B cells isolated from PBMCs of three healthy donors were similarly analyzed but no HLA-G transcripts were detected (data not shown).
Similar HLA-G expression analysis was performed on myeloma cells isolated by CD138 selection of bone marrow aspirates from eight myeloma patients. Multiple HLA-G transcripts were detected by RT-PCR in CD138-positive cell fractions (Table 1b) 
NK-92 cells express the HLA-G receptor ILT2, which can inhibit their cytotoxic activity against HLA-Gexpressing target cells (M8-HLA-G1)
The expression of HLA-G inhibitory receptors in NK-92 was analyzed. In contrast to KIR2DL4 surface expression, which is detectable but very low on NK-92, 17 ,28 these cells express high levels of ILT2.
To determine the importance of the HLA-G/ILT2 interaction in delivering inhibitory signals during NK-92-mediated killing, we examined the sensitivity of melanoma cell line M8 and its stable transfectant M8-HLA-G1 cells to NK92 cytotoxicity using a flow cytometry-based cytotoxicity assay. Parental M8 cells are HLA-Ipositive but do not express HLA-G protein, while a stable transfectant of this cell line, M8-HLA-G1, constructed and utilized as described in detail previously 37, 38 expresses the cell surface HLA-G1 isoform. CD107 mobilization is a measurement of effector activation to kill the target rather than the lysis of the target cells themselves and, therefore, provides a more accurate assessment of the impact of inhibitory signals. Results demonstrate that killing of M8-HLA-G1 by NK-92 was significantly lower than that of parental M8 cells (Supplementary Figure 1) . Sensitivity to NK92-mediated killing could be restored to M8-HLA-G1 cells by blocking HLA-G1 with the specific mAb 87G (Supplementary Figure 1) suggesting that the ILT2/HLA-G pathway is indeed important in controlling NK-92-mediated cytotoxicity toward HLA-G1-expressing targets.
Blocking of HLA-G increases the sensitivity of CLL cells to NK-mediated killing
To assess the contribution of HLA-G expression on CLL cells to their susceptibility to NK-mediated killing, cytotoxicity assays were performed in the absence and presence of a blocking antibody against HLA-G. Target cells were incubated with azide-free HLA-G mAb 87G at a concentration of 10 mg ml -1 for 30 min prior to coincubation with NK cells, and then cytotoxicity assay was performed as described.
Tumor-cell killing by NK-92 cells was significantly increased when HLA-G was blocked on CLL tumor cells as assessed in a cytotoxicity assay measuring caspase activation in target cell (Figure 3a) . Coordinately, in CD107 mobilization assays measuring NK cell activation to kill the target, blocking of HLA-G significantly increased NK cell degranulation in all samples tested (Figure 3b) . These results provide strong support for a contribution of HLA-G in protecting CLL cells from NKmediated attack.
Discussion
The nonclassical HLA class-I molecule, HLA-G, was first identified on cytotrophoblast, where it was shown to protect the semi-allogeneic fetus from maternal NK cells while its immunoregulatory action has been shown to contribute to graft acceptance and tumor escape. To date, the expression of HLA-G in hematological malignancies has been investigated in a number of studies [39] [40] [41] [42] [43] with conflicting findings, presumably due to the heterogeneity of the studied population or technical factors. Amiot et al. 39 investigating HLA-G expression in normal and malignant hematopoiesis found HLA-G transcripts only in T and B lymphocytes and a variable proportion of their malignant counterparts (6/15 ALL, 100% of B-NHLs, 20/30 CLL), no protein antigens were detected at the cell surface or in the cytosol of any of these cells. These authors also found increased plasma level of sHLA-G in 70% of CLL 54% of B-NHL and 45% of T-NHL and more recently in acute myeloid leukemia (AML). 40 A retrospective study investigating 51 leukemia samples, including 8 CLL did not detect HLA-G surface expression nor transcripts in CLL. 41 Notably, HLA-G expression has recently been reported in B-CLL and associated with an unfavorable outcome. 42 Flow cytometry analysis of CLL samples (n ¼ 47) showed surface expression of HLA-G in a variable proportion of tumor cells in all CLL samples examined that correlated with survival. The authors found that patients with o23% HLA-G-positive leukemic cells (n ¼ 37) had a longer progression-free survival than those with 423% HLA-G (n ¼ 10). Moreover, the level of HLA-G expression correlated with degree of immunosuppression as assessed by levels of IgG, total T cell numbers and CD4 T cells. Based upon these results, HLA-G was hypothesized to be a better prognostic factor than Zap-70 or CD38 status.
Leleu et al. 43 evaluated both total soluble HLA-class I and sHLA-G in 103 patients with newly diagnosed MM, 30 monoclonal gammopathy of undetermined significance (MGUS) and 30 healthy individuals to determine its prognostic value in relation to b2microglobulin (b2m), a common prognostic factor for MM. These parameters were found to be significantly lower in healthy individuals than in MM or MGUS. While sHLA-I varied across stages of MM, sHLA-G was higher in MM and MGUS regardless of the stage of the disease, concluding that sHLA-I but not sHLA-G could be used as an additional prognostic factor along with b2m.
The immunoregulatory role of HLA-G is now well established, including its inhibition of NK cytotoxicity against melanoma 22 and glioma, 23 however, no data exist demonstrating its potential contribution in protecting tumor cells from NK-mediated killing in hematological malignancies. The aim of this study was to evaluate the role of NK cells in MM and CLL, the two most prevalent adult hematological malignancies in the western hemisphere, first in the occurrence of the disease as well as their potential as a means of immunotherapy in these diseases. In this regard, we sought to assess the expression of HLA-G and its isoforms in CLL and MM and to determine its relevance to susceptibility to NK-mediated killing. MM1  G1/G5  MM2  ND  MM3  ND  MM4  ND  MM5  G1/G5,G3  MM6  ND  MM7  ND  MM8  G1/G5  MM9  G1/G5, G2/G4,  MM10  G1/G5, G2/G4, G3  MM11 G1/G5, G2/G4 MM12 ± G2/G4 MM13 G1/G5, ± G2/G4, G3
Abbreviations: MM, Multiple myeloma; ND, not determined; PIN, patient's identification number.
Cytotoxic activity of NK cells is regulated by a delicate balance between signals through activating and inhibitory receptors expressed by NK cells. While most NK inhibitory receptors are clonally distributed and, therefore, present on only a small proportion of circulating NK cells, LIR1/ILT2/CD85j and KIR2DL4, the two receptors for HLA-G are not clonally distributed. KIR2DL4 is expressed on all NK cells of an individual, and ILT2 on a subset of NK cells variable in size among different donors and also on most myelomonocytic cells, B cells, dendritic cells and subset of T cells. HLA-G expression may therefore represent a more universal mechanism of tumor escape. Because of the lack of inhibitory receptors corresponding to MHC class-I antigens present on target cell, and the absence of inhibitory signal, NK cells from allogeneic donors are thought to be more effective in killing tumor cells. This has encouraged a body of preclinical and clinical work on the basis of using allogeneic NK cells and initiated great interest and effort in exploiting NK-cell alloreactivity in bone marrow/stem cell transplantation to eliminate tumor cells in particular in hematological malignancies. However, tumor-cell susceptibility to NK cells can vary with the type of disease, as there can be heterogeneity within a specific malignancy. Chronic myelogenous leukemia (CML) cells are known to be very sensitive to NK cells and the most encouraging data from alloreactive NK trials were obtained with tumor cells of myeloid origin (AML). This knowledge is thus important to predict both the applicability and efficacy of any such therapy. Alternatively, NK activity itself may be altered in CML, AML and myelodysplastic syndromes (MDS) patients [33] [34] [35] as well as CLL and MM (G Maki, unpublished data). CLL and MM tumorcell susceptibility to NK-mediated killing was, therefore, investigated using both NK cells from unrelated healthy donors, as well as the highly cytotoxic NK cell line, NK-92. Results presented here utilize NK-92 as it has a very high cytotoxic activity and represents an excellent model system to assess NK susceptibility and possible means of tumor escape. We found that while myeloma cell lines are sensitive to NK-mediated killing, primary tumor cells from MM as well as CLL are overwhelmingly resistant to NK-mediated killing. To gain insight into molecular mechanisms of this resistance, we sought to assess the expression of HLA-G and its isoforms in CLL and MM and to determine its relevance to susceptibility to NK-mediated killing. We examined both HLA-G transcript and cell-surface protein expression to elucidate its role in protecting tumor cells from NK cells.
In contrast to KIR2DL4 surface expression, which is almost undetectable on NK-92, 17 ,28 these cells express high levels of ILT2. For NK-92 interaction with HLA-G, ILT2 is the relevant receptor. Using the melanoma cell line M8 and its HLA-G1-expressing transfectant M8-HLA-G1, the effectiveness of ILT2/ HLA-G pathway in protecting target cells from NK-92-mediated killing was confirmed. The importance of ILT2 as an inhibitory receptor for HLA-G has also been demonstrated via another NK cell line, NKL, despite high levels of surface expression of both ILT2 and KIR2DL4. 38 Herein we report the relative resistance of primary tumor cells from CLL and myeloma patients to NK-mediated killing and the presence of HLA-G-encoding mRNAs in these cells. With the exception of 2 out of 19 CLL, HLA-G transcripts were found in tumor cells from both CLL and MM patients, while being absent from their normal counterparts. Surface expression of HLA-G1 could be detected on variable proportion of CLL cells and was low or undetectable on primary myeloma cells and myeloma cell lines. In contrast to myeloma cell lines that were very sensitive to NK-mediated killing, patient-derived myeloma cells were mostly resistant to NK cells. Of the 19 CLL samples examined, only 5 were moderately sensitive (X15% kill at 20:1) while 14 were resistant (killing less than 10% at 20:1). Notably, blocking of HLA-G1 on CLL cells increased their susceptibility to NK-mediated killing regardless of their initial level of susceptibility to NK-mediated killing. With regard to CLL and myeloma samples with low or no surface expression of HLA-G1, we cannot exclude the contribution of other isoforms of HLA-G, specifically sHLA-G in vivo. Indeed both membrane-bound (mHLA-G) and soluble HLA-G (sHLA-G, either shed from the membrane or produced by soluble isoform-encoding mRNAs) have been shown to have immunosuppressive effect by either triggering of inhibitory signals on NK and T cells, or by induction of apoptosis on these cells. 18, 21 This immunosuppressive role can also be mediated through a recently defined process of 'acquired' HLA-G through a process of membrane transfer called 'trogocytosis'. The expression of HLA-G (mHLA-G or sHLA-G) on CLL or myeloma cells, bone marrow or blood can, therefore, be relevant to tumor escape not only by directly inhibiting NK cytotoxic function and conferring resistance to NK-mediated killing but also as a more general immunosuppressive factor affecting other immune effector cells such as T lymphocytes and dendritic cells. Moreover, HLA-G1 and -G5 molecules can exist as either b2m-free or-associated chain as monomers, disulfide-linked homodimers or oligomers 44 with differences in their binding affinity to receptors. Recent data support preferential binding of ILT2 for HLA-G dimers. 45 The lack of detection of HLA-G on the surface of myeloma cells that we tested, may therefore, also be due to these conformational features of HLA-G molecules which may not be recognized by our antibodies (MEM-G/9 and 87G).
This work investigated only tumor cell interaction with NK cells, and sHLA-G in the blood or BM was not investigated. Our results from HLA-G-blocking experiments demonstrate the relevance of HLA-G in the tumor escape from NK cells in these malignancies and imply that other mechanisms of NK resistance may also be in place. Although not directly investigated for MM in this study because of very low or undetectable surface expression, the relative resistance to NK-mediated killing and the presence of HLA-G mRNA in all myeloma samples examined strongly suggest a role for HLA-G in this resistance. These data suggest that although it may not on its own to determine resistance to NK cells, HLA-G may contribute to protecting CLL and potentially MM cells from NK-mediated killing.
Our findings on the expression of HLA-G in CLL cells confirm previous study by Nü ckel et al. reporting surface expression of HLA-G in a variable proportion of the cells on all CLL samples examined. While this study established a correlation between HLA-G expression level and the degree of immunosuppression and survival with a cutoff level of 23% HLA-G positivity, our data demonstrate for the first time the role of HLA-G in tumor NK resistance in hematological malignancies. This is the first report implicating HLA-G in protecting CLL and potentially MM cells from NK cells in primary patient derived tumor cells rather than in cell lines. Data with cell lines may not translate accurately to primary tumor cells particularly for diseases such as CLL and MM where the in vivo microenvironment plays important role in the pathophysilogy of the disease. These data justify further investigation into the role of HLA-G expression on these tumor cells of B origin in the pathophysiology of the disease and potential benefit from modulating HLA-G expression in improving the therapeutic outcome in the future. This knowledge could help predict efficacy and response to immunotherapy and allow designing better NK-based immunotherapy that could broaden the therapeutic spectrum in patients with B-CLL and multiple myeloma.
